Toboroz
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579· 3. fázis· Eli Lilly and Company· Forrás
Még nem toboroz
Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.
2025-524606-15-00· 3. fázis· Tecnimede-Sociedade Tecnico-Medicinal S.A.· Forrás
Fut, nem toboroz
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· 3. fázis· GlaxoSmithKline· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901· 3. fázis· Kailera· Forrás
Toboroz
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo
in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
2025-521562-95-00· 3. fázis· Mabxience Research S.L.· Forrás
Fut, nem toboroz
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875· 3. fázis· Kailera· Forrás
Toboroz
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051· 2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503· 2. fázis· Windward Bio· Forrás
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· 2. fázis· Inmagene LLC· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
NCT06958536· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053· 2. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325· 3. fázis· UCB Biopharma SRL· Forrás
Fut, nem toboroz
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus
2024-510584-37-00· 2. fázis· Zenas Biopharma (USA) LLC· Forrás
Fut, nem toboroz
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060· 2. fázis· Ipsen· Forrás
Meghívásos bevonás
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772· 2. fázis· Sanofi· Forrás
Meghívásos bevonás
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322· 3. fázis· UCB Biopharma SRL· Forrás